

## UNITED STATES PATENT AND TRADEMARK OFFICE

UNITED STATES DEPARTMENT OF COMMERCE United States Patent and Trademark Office Address: COMMISSIONER OF PATENTS AND TRADEMARKS Washington, D.C. 20231 www.uspto.gov

APPLICATION NO.	FILING DATE	FIRST NAMED INVENTOR	ATTORNEY DOCKET NO.	CONFIRMATION NO.	
09/913,494	08/16/2001	Winfried Linxweiler	MERCK 2289	2518	
23599	7590 03/26/2003				
MILLEN, WHITE, ZELANO & BRANIGAN, P.C. 2200 CLARENDON BLVD. SUITE 1400			EXAMINER		
			PAK, YONG D		
ARLINGTO	VA 22201		ART UNIT	PAPER NUMBER	
			1652		
			DATE MAILED: 03/26/2003		

Please find below and/or attached an Office communication concerning this application or proceeding.

		Application	No.	Applicant(s)				
Office Action Summary		09/913,494		LINXWEILER ET AL.				
		Examiner		Art Unit				
		Yong Pak		1652				
The MAILING DATE of this communication appears on the cover sheet with the correspondence address Period for Reply								
A SHORTENED STATUTORY PERIOD FOR REPLY IS SET TO EXPIRE 1 MONTH(S) FROM THE MAILING DATE OF THIS COMMUNICATION.  - Extensions of time may be available under the provisions of 37 CFR 1.136(a). In no event, however, may a reply be timely filed after SIX (6) MONTHS from the mailing date of this communication.  - If the period for reply specified above is less than thirty (30) days, a reply within the statutory minimum of thirty (30) days will be considered timely.  - If NO period for reply is specified above, the maximum statutory period will apply and will expire SIX (6) MONTHS from the mailing date of this communication.  - Failure to reply within the set or extended period for reply will, by statute, cause the application to become ABANDONED (35 U.S.C. § 133).  - Any reply received by the Office later than three months after the mailing date of this communication, even if timely filed, may reduce any earned patent term adjustment. See 37 CFR 1.704(b).  Status								
1)[	Responsive to communication(s) filed on _	<u> </u>						
2a) <u></u> □	This action is <b>FINAL</b> . 2b)	This action is n	ion-final.					
3) Since this application is in condition for allowance except for formal matters, prosecution as to the merits is closed in accordance with the practice under <i>Ex parte Quayle</i> , 1935 C.D. 11, 453 O.G. 213.  Disposition of Claims								
4)⊠ Claim(s) <u>1-17</u> is/are pending in the application.								
4	4a) Of the above claim(s) is/are withd	rawn from con	sideration.					
5)□	Claim(s) is/are allowed.							
6)□	Claim(s) is/are rejected.							
7)	7) Claim(s) is/are objected to.							
8) Claim(s) 1-17 are subject to restriction and/or election requirement.  Application Papers								
9) The specification is objected to by the Examiner.								
10)☐ The drawing(s) filed on is/are: a)☐ accepted or b)☐ objected to by the Examiner.								
Applicant may not request that any objection to the drawing(s) be held in abeyance. See 37 CFR 1.85(a).								
11) The proposed drawing correction filed on is: a) approved b) disapproved by the Examiner.								
If approved, corrected drawings are required in reply to this Office action.								
12) The oath or declaration is objected to by the Examiner.								
Priority under 35 U.S.C. §§ 119 and 120								
13) Acknowledgment is made of a claim for foreign priority under 35 U.S.C. § 119(a)-(d) or (f).								
a) ☐ All b) ☐ Some * c) ☐ None of:								
	1. Certified copies of the priority documents have been received.							
	2. Certified copies of the priority documents have been received in Application No							
<ul> <li>3. Copies of the certified copies of the priority documents have been received in this National Stage application from the International Bureau (PCT Rule 17.2(a)).</li> <li>* See the attached detailed Office action for a list of the certified copies not received.</li> </ul>								
14) Acknowledgment is made of a claim for domestic priority under 35 U.S.C. § 119(e) (to a provisional application).								
a) ☐ The translation of the foreign language provisional application has been received.  15) ☐ Acknowledgment is made of a claim for domestic priority under 35 U.S.C. §§ 120 and/or 121.								
Attachment(s)								
1) Notice 2) Notice	ce of References Cited (PTO-892) ce of Draftsperson's Patent Drawing Review (PTO-948) mation Disclosure Statement(s) (PTO-1449) Paper No(s			ry (PTO-413) Paper N Patent Application (P				

Application/Control Number: 09/913,494

Art Unit: 1652

## **DETAILED ACTION**

This application is a 371 of PCT/EP00/00978. The preliminary amendment filed August 16, 2001, amending claims 4, 7-10, 13 and 17, has been entered.

Claims 1-17 are pending.

## Election/Restrictions

Restriction is required under 35 U.S.C. 121 and 372.

This application contains the following inventions or groups of inventions which are not so linked as to form a single general inventive concept under PCT Rule 13.1.

In accordance with 37 CFR 1.499, applicant is required, in reply to this action, to elect a single invention to which the claims must be restricted.

Group I, claim(s) 1-3, drawn to a fusion protein comprising a glucose dehydrogenase.

Group II, claim(s) 4-6 and 11-12, drawn to DNA encoding the fusion protein of Group I, vector comprising said DNA, host cell comprising said DNA and a method of using said DNA.

Group III, claim(s) 7-10, drawn to a method of using the fusion protein of Group I as a detector.

Group IV, claim(s) 13-17, drawn to a method of using the fusion protein of Group I in a gel eletrophoresis.

The inventions listed as Groups I-IV do not relate to a single general inventive concept under PCT Rule 13.1 because, under PCT Rule 13.2, they lack the same or corresponding special technical features for the following reasons:

However, Sakhamuru et al. (from PTO-892) teach a recombinant fusion protein comprising of a glucose dehydrogenase.

Application/Control Number: 09/913,494

Art Unit: 1652

Therefore, the technical feature linking the inventions of Groups I-V does not constitute a special technical feature as defined by PCT Rule 13.2, as it does not define a contribution over the prior art.

The special technical feature of Group I is a fusion protein comprising a glucose dehydrogenase.

The special technical feature of Group II is a DNA encoding a fusion protein comprising a glucose dehydrogenase, vector comprising said DNA, host cell comprising said DNA and a method of using said DNA.

The special technical feature of Group III is a method of using a fusion protein comprising a glucose dehydrogenase as a detector.

The special technical feature of Group IV is a method of using a fusion protein comprising a glucose dehydrogenase in a gel eletrophoresis.

Applicant is advised that the reply to this requirement to be complete must include an election of the invention to be examined even though the requirement be traversed (37 CFR 1.143).

Applicant is reminded that upon the cancellation of claims to a non-elected invention, the inventorship must be amended in compliance with 37 CFR 1.48(b) if one or more of the currently named inventors is no longer an inventor of at least one claim remaining in the application. Any amendment of inventorship must be accompanied by a request under 37 CFR 1.48(b) and by the fee required under 37 CFR 1.17(i).

Any inquiry concerning this communication or earlier communications from the examiner should be directed to Yong Pak whose telephone number is 703-308-9363. The examiner can normally be reached on 8:00 A.M. to 4:30 P.M weekdays.

If attempts to reach the examiner by telephone are unsuccessful, the examiner's supervisor, Ponnathapu Achutamurthy can be reached on 703-308-3804. The fax phone numbers for the organization where this application or proceeding is assigned are 703-872-9306 for regular communications and 703-872-9307 for After Final communications.

Page 4

Application/Control Number: 09/913,494

Art Unit: 1652

Any inquiry of a general nature or relating to the status of this application or proceeding should be directed to the receptionist whose telephone number is 703-308-0196.

Yong Pak Patent Examiner

March 18, 2003